To this end, we employed gene signatures representative of E2F, PI3K, Myc, β-catenin, Src, and Ras pathway activation, as well as signatures of response to other commonly used cytotoxic agents in breast cancer (docetaxel, etoposide, vinorelbine and cisplatin), in the cohort of 133 patients. This evidence concerns the gene SRC and breast cancer.